-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GoSiPBARaHtFoUWrFVKQ1xA7sopASpHDe32hMF9lggwOpEmt6K94HOK8rIletZZ7 PF/Af/Gm6LyaDLtBtgF68Q== 0000950142-05-002228.txt : 20050808 0000950142-05-002228.hdr.sgml : 20050808 20050808171518 ACCESSION NUMBER: 0000950142-05-002228 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20050808 DATE AS OF CHANGE: 20050808 GROUP MEMBERS: FRANK H. PEARL GROUP MEMBERS: GEORGE SOROS GROUP MEMBERS: PERSEUS BIOTECH FUND PARTNERS, LLC GROUP MEMBERS: PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP GROUP MEMBERS: PERSEUS-SOROS PARTNERS, LLC GROUP MEMBERS: PERSEUSPUR, LLC GROUP MEMBERS: SFM AH LLC GROUP MEMBERS: SFM PARTICIPATION, L.P. GROUP MEMBERS: SOROS FUND MANAGEMENT LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MYOGEN INC CENTRAL INDEX KEY: 0001101052 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841348020 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79524 FILM NUMBER: 051006632 BUSINESS ADDRESS: STREET 1: 7575 WEST 103RD AVENUE STE 102 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 3034106666 MAIL ADDRESS: STREET 1: 7575 WEST 103RD AVENUE STE 102 CITY: WESTMINSTER STATE: CO ZIP: 80021 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PERSEUS SOROS BIOPHARMACEUTICAL FUND LP CENTRAL INDEX KEY: 0001111408 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ARMY & NAVY CLUB BLDG STREET 2: 1627 I ST NW STE 610 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: (212) 651-6389 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 30TH FL CITY: NEW YORK STATE: NY ZIP: 10106 SC 13D/A 1 sc13da1-myogen.txt AMENDMENT NO 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MYOGEN, INC. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 62856E104 (CUSIP Number) Adele Kittredge Murray, Esq. Perseus-Soros BioPharmaceutical Fund, LP 888 Seventh Avenue, 30th Floor New York, NY 10106 Tel. No.: (212) 651-6380 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) with a copy to Bruce A. Gutenplan, Esq. Paul, Weiss, Rifkind, Wharton & Garrison LLP 1285 Avenue of the Americas New York, New York 10019-6064 July 29, 2005 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject to this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [_]. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 62856E104 Page 2 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON Perseus-Soros BioPharmaceutical Fund, LP - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 1,670,650 (1) NUMBER OF ---------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 0 OWNED BY ---------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 1,670,650 (1) PERSON ---------------------------------------- WITH 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,670,650 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON PN - -------------------------------------------------------------------------------- - ------------ (1) Includes 183,908 shares of common stock, par value $.001 per share of Myogen, Inc. (the "Common Stock") issuable upon exercise of a warrant (the "Warrant"). (2) Assumes that there are 36,037,006 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant). CUSIP No. 62856E104 Page 3 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON Perseus-Soros Partners, LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 1,670,650 (1) NUMBER OF ----------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 0 OWNED BY ----------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 1,670,650 (1) PERSON ----------------------------------------- WITH 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,670,650 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 183,908 shares of Common Stock issuable upon exercise of the Warrant. (2) Assumes that there are 36,037,006 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant). CUSIP No. 62856E104 Page 4 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON Perseus BioTech Fund Partners, LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ----------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,670,650 (1) OWNED BY ----------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ----------------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,670,650 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,670,650 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 183,908 shares of Common Stock issuable upon exercise of the Warrant (2) Assumes that there are 36,037,006 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant). CUSIP No. 62856E104 Page 5 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON SFM Participation, L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ----------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,670,650 (1) OWNED BY ----------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ----------------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,670,650 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,670,650 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON PN - -------------------------------------------------------------------------------- - ------------ (1) Includes 183,908 shares of Common Stock issuable upon exercise of the Warrant. (2) Assumes that there are 36,037,006 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant). CUSIP No. 62856E104 Page 6 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON SFM AH LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ----------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,670,650 (1) OWNED BY ----------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ----------------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,670,650 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,670,650 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 183,908 shares of Common Stock issuable upon exercise of the Warrant. (2) Assumes that there are 36,037,006 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant). CUSIP No. 62856E104 Page 7 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON Perseuspur, L.L.C. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 ---------------------------------------- NUMBER OF 8 SHARED VOTING POWER SHARES 1,670,650 (1) BENEFICIALLY ---------------------------------------- OWNED BY 9 SOLE DISPOSITIVE POWER EACH 0 REPORTING ---------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER WITH 1,670,650 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,670,650 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [X] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO - -------------------------------------------------------------------------------- - ------------ (1) Includes 183,908 shares of Common Stock issuable upon exercise of the Warrant. (2) Assumes that there are 36,037,006 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant). CUSIP No. 62856E104 Page 8 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON Frank H. Pearl (in the capacity described herein) - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION United States - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 NUMBER OF ----------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 1,678,150 (1) OWNED BY ----------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 0 PERSON ----------------------------------------- WITH 10 SHARED DISPOSITIVE POWER 1,678,150 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,678,150 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.7% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------- - ------------ (1) Includes (i) 183,908 shares of Common Stock issuable upon exercise of the Warrant and (ii) 7,500 shares of Common Stock underlying vested options issued to Dr. Andrew N. Schiff, in his capacity as director of the Company (the "Options"). (2) Assumes that there are 36,044,506 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant and 7,500 shares issuable upon exercise of the Options). CUSIP No. 62856E104 Page 9 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON George Soros (in the capacity described herein) - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION United States - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 ----------------------------------------- NUMBER OF 8 SHARED VOTING POWER SHARES 1,678,150 (1) BENEFICIALLY ----------------------------------------- OWNED BY 9 SOLE DISPOSITIVE POWER EACH 0 REPORTING ----------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER WITH 1,678,150 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,678,150 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.7% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON IA - -------------------------------------------------------------------------------- - ------------ (1) Includes (i) 183,908 shares of Common Stock issuable upon exercise of the Warrant and (ii) 7,500 shares of Common Stock underlying vested the Options. (2) Assumes that there are 36,044,506 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant and 7,500 shares issuable upon exercise of the Options). CUSIP No. 62856E104 Page 10 of 17 SCHEDULE 13D 1 NAME OF REPORTING PERSON Soros Fund Management LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not Applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 ----------------------------------------- NUMBER OF 8 SHARED VOTING POWER SHARES 1,678,150 (1) BENEFICIALLY ----------------------------------------- OWNED BY 9 SOLE DISPOSITIVE POWER EACH 0 REPORTING ----------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER WITH 1,678,150 (1) - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,678,150 (1) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.7% (1)(2) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO; IA - -------------------------------------------------------------------------------- - ------------ (1) Includes (i) 183,908 shares of Common Stock issuable upon exercise of the Warrant and (ii) 7,500 shares of Common Stock underlying vested the Options. (2) Assumes that there are 36,044,506 shares of Common Stock outstanding (includes 183,908 shares issuable upon exercise of the Warrant and 7,500 shares issuable upon exercise of the Options). CUSIP No. 62856E104 Page 11 of 17 Pursuant to Rule 13d-2(a) of Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the "Act"), the undersigned hereby amend their Schedule 13D Statement, dated September 29, 2004 (the "Schedule 13D") relating to the common stock, par value $.001 per share (the "Common Stock"), of Myogen, Inc., a Delaware corporation (the "Company"). Item 1. SECURITY AND ISSUER. No material change. Item 2. IDENTITY AND BACKGROUND. (a), (b), (c) and (f). The first paragraph of these sections is hereby amended and restated as follows: "This Schedule 13D is being filed on behalf of each of the following persons (each a "Reporting Person" and collectively, the "Reporting Persons"): (i) Perseus-Soros BioPharmaceutical Fund, LP, a Delaware limited partnership ("Perseus-Soros"); (ii) Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners"); (iii) Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners"); (iv) SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"); (v) SFM AH, LLC, a Delaware limited liability company ("SFM AH"); (vi) Perseuspur, L.L.C., a Delaware limited liability company ("Perseuspur"); (vii) Mr. Frank H. Pearl ("Mr. Pearl"); (viii) Mr. George Soros ("Mr. Soros"); and (ix) Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC")." These sections are also hereby amended by adding the following: "On October 21, 2004, Perseus EC merged into Perseuspur. On such date, Perseus EC ceased to be a Reporting Person." (d) and (e). The first paragraph of these sections is hereby amended and restated as follows: "On December 27, 2002, Mr. Soros appealed a decision of the 11e Chambre du Tribunal Correctionnel in Paris, France that fined him 2.2 million euros on December 20, 2002 based on a finding of insider trading with respect to trading in securities of Societe Generale in 1988. On March 24, 2005, the Paris Court of Appeal affirmed the decision of the 11e Chambre du Tribunal Correctionnel. Mr. Soros intends to file a further appeal at the French Cour de Cassation and, if that appeal is not successful, an additional action with the European Court of Justice. Mr. Soros elected to provide the foregoing information on a voluntary basis." Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. No material change. CUSIP No. 62856E104 Page 12 of 17 Item 4. PURPOSE OF TRANSACTION. This section is hereby amended by adding the following: "Since the filing of the Schedule 13D, the Reporting Persons have disposed of more than one percent of the Company's outstanding Common Stock. As a result of the sales described in Item 5(c) of this Amendment No. 1 to the Schedule 13D, the Reporting Persons ceased to be beneficial owners of more than five percent of the Company's outstanding Common Stock." Item 5. INTEREST IN SECURITIES OF THE ISSUER. (a) Based on calculations made in accordance with Rule 13d-3(d), as of the date hereof and after giving effect to the exercise of the Warrant, each of the Reporting Persons, except SFM LLC, Mr. Soros and Mr. Pearl, may be deemed to beneficially own an aggregate of 1,670,650 shares of Common Stock. As of August 4, 2005, there were 35,853,098 shares of Common Stock outstanding based on information from the Company. Based on calculations made in accordance with Rule 13d-3(d), as of the date hereof and after giving effect to the exercise of the Warrant, each of the Reporting Persons, except SFM LLC, Mr. Soros and Mr. Pearl, may be deemed to beneficially own approximately 4.6% of the outstanding shares of Common Stock. After giving effect to the exercise of the Warrant and options to purchase Common Stock that were granted to Dr. Andrew N. Schiff, a director of the Company, employed by an entity affiliated with the Reporting Persons (the "Options"), SFM LLC, Mr. Soros and Mr. Pearl each may be deemed to beneficially own an aggregate of 1,678,150 shares of Common Stock. Based on the above calculations and information, this represents approximately 4.7% of the outstanding shares of Common Stock. (b) (i) Each of Perseus-Soros and Perseus-Soros Partners may be deemed to have sole power to direct the voting and disposition of the 1,670,650 shares of Common Stock that may be deemed to be beneficially owned by Perseus-Soros (assumes the exercise of the Warrant held for the account of Perseus-Soros). (ii) By virtue of the relationships between and among the Reporting Persons described in Item 2 of this Schedule 13D, each of the Reporting Persons, other than Perseus-Soros and Perseus-Soros Partners may be deemed to share the power to direct the voting and disposition of the 1,670,650 shares of Common Stock beneficially owned by Perseus-Soros (assumes the exercise of the Warrant held for the account of Perseus-Soros). (iii) By virtue of the relationships between and among the Reporting Persons described in Item 2 of this Schedule 13D, each of SFM LLC, Mr. Soros and Mr. Pearl may be deemed to share the power to direct the voting and disposition of the 7,500 shares of Common Stock issuable upon exercise of the Options. (c) During the past 60 days, shares beneficially owned by the Reporting Persons have been sold in open market transactions on the Nasdaq National Market as follows: DATE NO. OF SHARES SOLD AVERAGE PRICE PER SHARE ---- ------------------ ----------------------- 7/29/05 400,400 $11.0518 8/1/05 350,000 $11.1705 8/2/05 360,000 $14.2726 CUSIP No. 62856E104 Page 13 of 17 (d) No material change. (e) On August 2, 2005, the Reporting Persons ceased to be beneficial owners of more than five percent of the Company's outstanding Common Stock. Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. No material change. Item 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit 7: Joint Filing Agreement, dated August 8, 2005, among (i) Perseus-Soros BioPharmaceutical Fund, LP, (ii) Perseus-Soros Partners, LLC, (iii) Perseus BioTech Fund Partners, LLC, (iv) SFM Participation, L.P., (v) SFM AH LLC, (vi) Frank H. Pearl, (vii) George Soros, (viii) Soros Fund Management LLC, and (ix) Perseuspur, LLC. CUSIP No. 62856E104 Page 14 of 17 SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: August 8, 2005 PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP By: Perseus-Soros Partners, LLC, General Partner By: SFM Participation, L.P., Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel PERSEUS-SOROS PARTNERS, LLC By: SFM Participation, L.P. Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel PERSEUS BIOTECH FUND PARTNERS, LLC By: Perseuspur, L.L.C. Managing Member By: /s/ Rodd Macklin ---------------------------------------- Name: Rodd Macklin Title: Secretary and Treasurer PERSEUSPUR, L.L.C. By: /s/ Rodd Macklin ---------------------------------------- Name: Rodd Macklin Title: Secretary and Treasurer CUSIP No. 62856E104 Page 15 of 17 MR. FRANK H. PEARL By: /s/ Rodd Macklin ---------------------------------------- Name: Rodd Macklin Title: Attorney-in-Fact SFM PARTICIPATION, L.P. By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel SFM AH LLC By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel MR. GEORGE SOROS By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Attorney-in-Fact SOROS FUND MANAGEMENT LLC By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel EX-99 2 ex_7sc13da1-myogen.txt EXHIBIT 7 CUSIP No. 62856E104 Page 16 of 17 EXHIBIT 7 JOINT FILING AGREEMENT Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit (the "Schedule 13D"), and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned. This Agreement may be executed in one or more counterparts. Dated: August 8, 2005 PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP By: Perseus-Soros Partners, LLC, General Partner By: SFM Participation, L.P., Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel PERSEUS-SOROS PARTNERS, LLC By: SFM Participation, L.P. Managing Member By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel PERSEUS BIOTECH FUND PARTNERS, LLC By: Perseuspur, L.L.C. Managing Member By: /s/ Rodd Macklin ---------------------------------------- Name: Rodd Macklin Title: Secretary and Treasurer CUSIP No. 62856E104 Page 17 of 17 PERSEUSPUR, L.L.C. By: /s/ Rodd Macklin ---------------------------------------- Name: Rodd Macklin Title: Secretary and Treasurer MR. FRANK H. PEARL By: /s/ Rodd Macklin ---------------------------------------- Name: Rodd Macklin Title: Attorney-in-Fact SFM PARTICIPATION, L.P. By: SFM AH LLC General Partner By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel SFM AH LLC By: Soros Fund Management LLC, Managing Member By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel MR. GEORGE SOROS By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Attorney-in-Fact SOROS FUND MANAGEMENT LLC By: /s/ Jay Schoenfarber ---------------------------------------- Name: Jay Schoenfarber Title: Assistant General Counsel -----END PRIVACY-ENHANCED MESSAGE-----